MPM BioVentures 2014, L.P. is 10% Owner at iTeos Therapeutics, Inc. (ITOS). They have made 7 open-market trades across 3 companies since 2019, most recently 2026-09-09.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $21K since 2020, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| HARP | 4,274,425 | $98.4M |
| ITOS | 3,141,158 | $31.9M |
| TRDA | 3,885,115 | $17.0M |
| HOWL | 5,836,240 | $5.7M |
| Total | $152.9M |
Shares reported on the most recent Form 4, priced at the 2026-09-09 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 67% | 100% | — |
| Avg Move | -0.6% | -13.3% | — |
| Scored | 6 | 6 | 2 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TRDA | SELL | 2026-09-04 | 2026-09-09 | $7.33 | $1.9M | -3.3% | -17.2% | — |
| TRDA | SELL | 2026-09-01 | 2026-09-03 | $7.14 | $617K | -2.3% | -22.4% | — |
| TRDA | SELL | 2026-08-27 | 2026-08-31 | $7.08 | $616K | -2.9% | -9.4% | — |
| TRDA | SELL | 2026-08-24 | 2026-08-26 | $7.36 | $462K | +7.3% | -12.7% | — |
| HOWL | SELL · 10b5-1 | 2025-11-07 | 2025-11-12 | $1.13 | $438K | -8.7% | +2.8% | -32.9% |
| ITOS | SELL · 10b5-1 | 2021-10-15 | 2021-10-18 | $27.45 | $469K | -2.7% | +21.8% | +37.4% |
| ITOS | SELL · 10b5-1 | 2021-10-12 | 2021-10-14 | $27.12 | $799K | -3.3% | +9.2% | +46.8% |
| ITOS | SELL | 2021-09-14 | 2021-09-16 | $27.74 | $2.0M | -7.5% | -3.1% | +30.9% |
| ITOS | SELL · 10b5-1 | 2021-04-09 | 2021-04-13 | $29.99 | $4K | -6.0% | -11.9% | -0.4% |
| ITOS | BUY | 2020-07-28 | 2020-07-29 | $19.00 | $21K | +52.1% | +55.9% | +29.0% |
| HARP | SELL | 2019-02-12 | 2019-02-14 | $14.00 | $21K | +5.1% | -14.7% | -29.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.